Anämie bei chronischen Erkrankungen
Begutachtet von Dr Hayley Willacy, FRCGP Zuletzt aktualisiert von Dr Colin Tidy, MRCGPZuletzt aktualisiert 14. Juni 2022
Erfüllt die redaktionelle Richtlinien
- HerunterladenHerunterladen
- Teilen
- Language
- Diskussion
- Ask Patient
- Audio-Version
- Zu bevorzugten Quellen bei Google hinzufügen
Medizinische Fachkräfte
Fachartikel sind für die Nutzung durch Gesundheitsfachkräfte konzipiert. Sie werden von britischen Ärzten verfasst und basieren auf Forschungsergebnissen sowie britischen und europäischen Richtlinien. Sie finden möglicherweise die Anämie Artikel nützlicher oder einer unserer anderen Gesundheitsartikel.
Wichtige Informationen |
|---|
The World Health Organization's criterion for anaemia in adult men is haemoglobin (Hb) values less than 130 g/L, non-pregnant women less than 120 g/L and pregnant women less than 110 g/L. Children aged 6 months to 6 years are considered anaemic at Hb levels less than 110 g/L, and children aged 6-11 years are considered anaemic when Hb levels are less than 115 g/L. |
Anaemia of chronic disease (ACD) may be secondary to:2
Chronic infection - eg, Tuberkulose.
Inflammation - eg, rheumatoide Arthritis, subacute lupus erythematosus (SLE).
Neoplasie.
An endocrine condition - eg, Hypothyreose, Hypopituitarismus, Addison-Krankheit.
Pathogenese
Anaemia of chronic disease (ACD) is still not fully understood. Different causes contribute to anaemia in chronic diseases, including diversion of iron, reduced erythropoiesis and reduced response to erythropoietin.
Interleukin-6 appears to be the central mediator of ACD in a range of inflammatory diseases, including end-stage kidney disease and rheumatoid arthritis.3
Anaemia of chronic disease is associated with hyposideraemia (low serum iron) and altered iron transport. Cytokines are implicated by reducing erythropoiesis and increasing iron sequestration in the reticuloendothelial system.4
Interleukin-6 induces the expression of hepcidin, which suppresses the expression of the iron transporter, ferroportin-1, so inhibiting the absorption of iron from the duodenum and the release of iron from the reticuloendothelial system.3
Hepcidin is a peptide hormone produced by the liver and is a key regulator of iron homeostasis.5
Hepcidin binds to the iron export protein, ferroportin, causing ferroportin to be phosphorylated and degraded in lysosomes.4
Hepcidin inhibits iron release from the reticuloendothelial system. Increased expression of hepcidin also leads to decreased iron absorption and iron-deficient anaemia. The regulation of iron absorption across the epithelium of the proximal small intestine is essential for maintaining body iron concentrations.4
The anaemia of chronic kidney disease is thought to be slightly different. See also the separate Anaemia in Chronic Kidney Disease Artikel.
Präsentation
The presentation of anaemia of chronic disease may be quite subtle in a patient who already has chronic disease. The presentation may include the new onset or increased tiredness, pallor, breathlessness and tachycardia.
Untersuchungen
ACD typically occurs despite adequate reticuloendothelial iron stores.
Reduced serum iron, transferrin and total iron-binding capacity.
Exclusion of a mixed cause for anaemia - B12 and folate levels.
Measuring serum ferritin is essential in investigating unexplained anaemia:
Serum ferritin concentration is directly related to reticuloendothelial iron stores, and normally 1 μg/L serum ferritin roughly corresponds to about 8 mg of storage iron.
Normal or raised ferritin is typical in ACD.6 This is because of the increased storage and retention of iron within the reticuloendothelial system. There are also increased ferritin levels due to immune activation accompanying the chronic disease.
In the presence of inflammation, ferritin concentrations may remain normal even when reticuloendothelial iron stores are absent.
High erythrocyte sedimentation rate (ESR).
Red cells are often normochromic, normocytic but may be hypochromic, microcytic (as frequently seen in rheumatoid arthritis and Crohn's disease).
Bone marrow examination for iron is the definitive test for deficiency - very uncomfortable and expensive.
Estimation of soluble transferrin receptor (if available):
Measurement of soluble transferrin receptor provides a marker of bone marrow iron stores and improves the diagnosis of iron-deficiency anaemia, therefore helping to differentiate between iron-deficiency anaemia and ACD.7
The test is much more expensive than ferritin measurement.
Bone marrow examination for the sole purpose of assessing iron stores is rarely justifiable.8
Differentialdiagnose2
Other causes of anaemia, particularly Eisenmangelanämie.
Any other cause of general deterioration in a patient with chronic disease.
Behandlung9
Treatment options involve the use of erythropoiesis-stimulating agents, blood transfusion, and iron supplementation, in addition to treating the underlying disease.
Pharmakologische Behandlung
The degree of anaemia is often mild and does not require treatment.
Iron supplements should only be used for patients with established iron deficiency.
Transfusion of packed red blood cells should be reserved for patients who have severe, symptomatic anaemia. This is a palliative measure only and its use should be weighed against the associated risks with transfusion - eg, volume overload, iron overload and transfusion reaction.
Novel erythropoiesis-stimulating protein (NESP) - darbepoetin alfa - stimulates erythropoiesis by the same mechanism as recombinant human erythropoietin (rHuEPO) but it is biochemically distinct:
It has a threefold greater serum half-life and can maintain Hb levels as effectively as rHuEPO in anaemic patients with chronic kidney disease, with less frequent dosing.10
Also, consider erythropoiesis-stimulating agents in rheumatoid arthritis, heart failure and cancer.11 12
Prognose
Usually this will depend on the underlying cause of the anaemia. However, the severity of the anaemia and the speed with which it developed can play a significant role. Similarly, the age of the patient and the existence of other comorbid conditions influence outcome.
Exklusive Updates für medizinisches Fachpersonal
Bleiben Sie informiert mit den neuesten klinischen Updates, professionellen Einblicken und evidenzbasierten Leitlinien. Der Patient Pro-Newsletter stellt wesentliche Inhalte für Gesundheitsfachkräfte zusammen – direkt in Ihren Posteingang geliefert.
Durch das Abonnieren akzeptieren Sie unsere Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.
Weiterführende Lektüre und Referenzen
- Newhall DA, Oliver R, Lugthart S; Anaemia: A disease or symptom. Neth J Med. 2020 Apr;78(3):104-110.
- Hämoglobinkonzentrationen zur Diagnose von Anämie und Beurteilung des Schweregrads; Weltgesundheitsorganisation, 2011
- Cullis J; Anaemia of chronic disease. Clin Med (Lond). 2013 Apr;13(2):193-6. doi: 10.7861/clinmedicine.13-2-193.
- Raj DS; Role of Interleukin-6 in the Anemia of Chronic Disease. Semin Arthritis Rheum. 2008 Mar 11;.
- Guidi GC, Lechi Santonastaso C; Advancements in anemias related to chronic conditions. Clin Chem Lab Med. 2010 Sep;48(9):1217-26. doi: 10.1515/CCLM.2010.264.
- Ganz T, Nemeth E; Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012 Sep;1823(9):1434-43. doi: 10.1016/j.bbamcr.2012.01.014. Epub 2012 Jan 26.
- Weiss G, Goodnough LT; Anemia of chronic disease. N Engl J Med. 2005 Mar 10;352(10):1011-23.
- Koulaouzidis A, Said E, Cottier R, et al; Soluble transferrin receptors and iron deficiency, a step beyond ferritin. A systematic review. J Gastrointestin Liver Dis. 2009 Sep;18(3):345-52.
- Guideline for the laboratory diagnosis of functional iron deficiency; British Committeee for Standards in Haematology (May 2013)
- Madu AJ, Ughasoro MD; Anaemia of Chronic Disease: An In-Depth Review. Med Princ Pract. 2017;26(1):1-9. doi: 10.1159/000452104. Epub 2016 Sep 28.
- Macdougall IC; Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol. 2008 Jan;3(1):200-7. Epub 2007 Dec 12.
- Ngo K, Kotecha D, Walters JA, et al; Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD007613.
- Scrijvers D, Roila F; Erythropoiesis-stimulating agents in cancer patients: ESMO recommendations for use. Ann Oncol. 2009 May;20 Suppl 4:159-61.
Über den RezensentenVollständige Biografie anzeigen

Dr Hayley Willacy, FRCGP
Allgemeinmediziner, Medizinischer Autor
MBChB (1992), DRCOG, DFFP, MRCOG (Part 1) MRCGP (2007), DFSRH (2013), MSc - medical education (2020)
Dr. Hayley Willacy war eine NHS-Hausärztin, die in Nordwestengland arbeitete und 2022 nach 30 Jahren aus der klinischen Praxis ausschied.
Artikelverlauf
Artikel auch verfügbar in Englisch, Deutsch, Spanisch, Französisch, Italienisch, Portugiesisch, Hindi, Hebräisch, Arabisch, und Schwedisch.
Nächste Überprüfung fällig: 13. Juni 2027
14. Juni 2022 | Neueste Version
Mehr in Geschichte und Untersuchung
- Ambulante Blutdrucküberwachung
- Verschwommene Sicht
- AktualisiertKachexie
- Cauda-equina-Syndrom
- Brustschmerzen
- Dermatologische Anamnese und Untersuchung
- Epiphora
- Wachstumsstörungen bei Kindern
- Fieber und Nachtschweiß
- Blähungen und Winde
- Foster-Kennedy-Syndrom
- Pilzinfektionen der Nägel
- Hypothermie
- Schwellung der Papille
- Pädiatrische Untersuchung
- Anhaltender Durchfall oder Erbrechen
- Pupillenanomalien
- Speicheldrüsenerkrankungen
- Schwere und teilweise Sehbehinderung
- Hodenhochstand


